Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate.
about
Emerging Threats in Antifungal-Resistant Fungal PathogensA Novel Zn2-Cys6 Transcription Factor AtrR Plays a Key Role in an Azole Resistance Mechanism of Aspergillus fumigatus by Co-regulating cyp51A and cdr1B ExpressionsDiscovery of a HapE mutation that causes azole resistance in Aspergillus fumigatus through whole genome sequencing and sexual crossingTranscriptome Profile of the Response of Paracoccidioides spp. to a Camphene Thiosemicarbazide DerivativeAntifungal Therapy: New Advances in the Understanding and Treatment of MycosisTriazole Resistance in Aspergillus Species: An Emerging Problem.Phylogenetic analysis of fungal ABC transporters.Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus.Regulatory circuitry governing fungal development, drug resistance, and disease.Passive surveillance for azole-resistant Aspergillus fumigatus, United States, 2011-2013Resistance to antifungals that target CYP51.Aspergillus fumigatus C-5 sterol desaturases Erg3A and Erg3B: role in sterol biosynthesis and antifungal drug susceptibility.Elucidating drug resistance in human fungal pathogens.Identification of novel genes conferring altered azole susceptibility in Aspergillus fumigatus.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Drug strategies targeting CYP51 in neglected tropical diseasesMultiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole.Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs.Global transcriptome changes underlying colony growth in the opportunistic human pathogen Aspergillus fumigatus.Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, JapanRNA-Seq Reveals OTA-Related Gene Transcriptional Changes in Aspergillus carbonarius.Rapid detection of triazole antifungal resistance in Aspergillus fumigatus.Multidrug resistance in fungicyp51A-Based mechanisms of Aspergillus fumigatus azole drug resistance present in clinical samples from Germany.Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact.Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistanceEfflux-mediated antifungal drug resistance.Antifungal drug resistance mechanisms.Azole resistance in Candida glabrata: coordinate upregulation of multidrug transporters and evidence for a Pdr1-like transcription factor.In vitro evolution of itraconazole resistance in Aspergillus fumigatus involves multiple mechanisms of resistance.Pharmacology and clinical use of voriconazole.Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection.Azole resistance in Aspergillus fumigatus: a new challenge in the management of invasive aspergillosis?The impact of azole resistance on aspergillosis guidelines.Yeast ABC proteins involved in multidrug resistance.Multidrug resistance in fungi: regulation of transporter-encoding gene expression.Exploring azole antifungal drug resistance in Aspergillus fumigatus with special reference to resistance mechanisms.Mechanisms of Antifungal Drug Resistance.Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene.The molecular mechanism of azole resistance in Aspergillus fumigatus: from bedside to bench and back.
P2860
Q26750816-94C8FDA8-DBEF-47F5-93B3-220FFD8A14B6Q28468399-1598509D-65B8-423A-9DB5-2C74B1C26F5EQ28485433-AD158097-1CEC-4EF5-A175-F7721CC770C3Q28545865-691BCB8D-B8DD-4940-A8A1-E71BD10196C1Q28818603-09107E03-062A-42B3-8C89-C70B72843A67Q30235566-10D9D717-AA00-4D92-AB25-319E80F4C424Q33541266-BFA184A2-B1CC-400B-958B-72A6FDED5378Q33857685-F32EA536-F9AA-4BA1-BBCD-FAF31EB3C287Q34190284-638D1869-1813-4F87-96F7-FA32A1A4EDAFQ34259732-9AE928AD-AC4A-4FD9-BF1B-117F90ED06D6Q34276700-8A2E6577-7AF4-4E3C-A49F-091EC5B0DB4EQ34352270-114E08E9-EA42-4EEF-9138-96C4F8DABE2EQ34419351-1747035C-AC74-414B-887B-59BD2D729C60Q34452089-8D4A1AAB-BFD5-4EF2-8DA0-5F68D90CE6BDQ34532546-3A331642-CD29-4C64-8D93-D08DCE68D653Q34622554-133CCF53-DE5A-4397-8E0D-8DF3BDA0D589Q34940421-D69A8D46-EFF3-4F4E-BB6C-7F2AFDFC501AQ35124469-38B352A4-73EE-49CF-AE3A-DFA3F29ED553Q35666165-E9E37413-2B27-4F46-9CB2-F5978377A6E7Q35666518-9852AF45-85FB-42B8-AD69-060B60C0593EQ35893805-F9142F25-A262-4BE7-92FB-A5B27E81AFA9Q36539892-D6850DFB-85A0-4CD8-A58C-CBF6D74613BEQ36943181-95EFE5E8-36F0-4BBA-95F9-6CECB356C411Q37036556-AEB2B0FE-2016-488F-B5C6-918853B162C4Q37048679-9F0359D0-7F7D-425D-BE61-8C155E4EE13AQ37122826-8AB7B799-36CF-444C-AD67-5FD932E26A0AQ37156645-1C4E538C-B96A-4A45-ACF6-4861C054001EQ37463223-A6C8BE86-56E4-4D64-91C8-82EC8736CDF7Q37568906-9B41A942-16B2-4C38-AA44-45AA341736F3Q37598624-5341B570-1EEC-4787-9CA1-1BF81BAAC912Q37641375-1814C254-2F19-44A3-A4A8-2240AF9C17F7Q37783285-BD530A71-3C95-45B9-84ED-CCE90ABA4657Q37859397-4C39EE86-E08C-4187-A9FC-9A7D67376115Q38066615-F07DDEC4-EDE5-48FC-A7CC-65693DFFEF5CQ38168143-EB2FAC86-E450-4A0E-8A60-253DAD0E6EDBQ38209314-F5F0392D-5585-4B3F-9E14-A9D8D76943A6Q38222570-51388A00-8F4C-48A8-A2C7-18A9D27C7D4EQ38266675-92DC84C8-13A6-4FEA-9BBA-EB3A14E7AE28Q38283306-B3723776-72EF-45EF-9B34-93A8B0D700EAQ38334381-69328187-AAE9-46B4-9D1C-2B942E2AF845
P2860
Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Increased expression of a nove ...... le resistant clinical isolate.
@en
Increased expression of a nove ...... le resistant clinical isolate.
@nl
type
label
Increased expression of a nove ...... le resistant clinical isolate.
@en
Increased expression of a nove ...... le resistant clinical isolate.
@nl
prefLabel
Increased expression of a nove ...... le resistant clinical isolate.
@en
Increased expression of a nove ...... le resistant clinical isolate.
@nl
P2093
P1476
Increased expression of a nove ...... le resistant clinical isolate.
@en
P2093
Graham K Dixon
Ian S Roberts
Jacques Bille
John W Slaven
Michael J Anderson
P304
P356
10.1016/S1087-1845(02)00016-6
P577
2002-08-01T00:00:00Z